Global Blood Therapeutics (GBT) Reports Q1 Loss of $0.60/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Global Blood Therapeutics (GBT) Reports Q1 Loss of $0.60/Share

Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results

May 1, 2017 4:05 PM EDT

SOUTH SAN FRANCISCO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported business progress and financial results for the first quarter ended March 31, 2017.

"We continue to make important progress advancing our lead product candidate, GBT440, across both our sickle cell disease (SCD) and idiopathic pulmonary fibrosis (IPF) indications, said Ted W. Love, M.D., president and chief executive officer of GBT. We are focused on activating new clinical trial sites for our pivotal HOPE Study to support ongoing enrollment and look forward to highlighting preliminary... More